|
목적 : To evaluate the role of intravitreal aflibercept injection (IAI) as a treatment for eyes with acute central serous chorioretinopathy (CSC).
방법 : Patients with symptomatic CSC of less than 6 months received a single IAI, and followed up at 2, 4 and 8 weeks without additional treatment. Best-corrected visual acuity (BCVA), central subfoveal foveal thickness (CSFT) and subfoveal choroidal thickness were assessed at baseline and at regular follow-ups.
결과 : A total of 35 eyes from 35 patients with the mean age of 51.7±9.6 years (range, 31 to 66 years) were enrolled in the study. The mean logMAR BCVA improved from 0.34±0.21 at baseline to 0.23±0.18 at 8 weeks (P=.019). The mean subfoveal choroidal thickness decreased from 439 μm at baseline to 419 μm and 423 μm at 2 and 4 weeks (P<.001, P<.001, respectively) compared to the baseline, and returned to 438 μm at 8 weeks (P=.020). The mean CSFT also decreased until 4 weeks but rebounded at 8 weeks. At 2 months after a single IAI, complete absorption of subretinal fluid rate was noted in 34.3%.
결론 : A single IAI for acute CSC induced a transient decrease in subfoveal choroidal thickness and CSFT which implies that IAI may have a pharmacologic effect on the underlying choroid in acute CSC. Further comparative studies are required to determine the long-term benefits of IAI in acute CSC.
|